Drug Information

Drug (ID: DG01873) and It's Reported Resistant Information

• Name: LY2780301
• Synonyms: LY2780301
• Indication:
  In total 1 Indication(s)
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Phase 1; [1]
• Target: Ribosomal protein S6 kinase (S6K); NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  RTDM: Regulation by the Disease Microenvironment

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Colon cancer [ICD-11: 2B90]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Regulation by the Disease Microenvironment (RTDM)

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.E545K (c.1633G>A)
• Sensitive Disease: Colon cancer [ICD-11: 2B90.1]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: .; N.A.
• In Vivo Model: Female athymic nude-Foxn1 nu mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Pharmacokinetic studies; Pharmacokinetic studies; Antitumor activity

References

• Ref 1: A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancerInvest New Drugs. 2015 Jun;33(3):710-9. doi: 10.1007/s10637-015-0241-7. Epub 2015 Apr 24.